Engh R A, Girod A, Kinzel V, Huber R, Bossemeyer D
Abteilung Strukturforschung II, Max-Planck Institute for Biochemistry, D-82152 Martinsried, Federal Republic of Germany.
J Biol Chem. 1996 Oct 18;271(42):26157-64. doi: 10.1074/jbc.271.42.26157.
The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling. Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 A) and with H89 (2.3 A) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.
在高度多样的细胞信号通路中发现了数百种不同的蛋白激酶,这与已知的细胞信号调节剂数量少得多形成了鲜明对比。其中,H系列蛋白激酶抑制剂(1-(5-异喹啉磺酰基)-2-甲基哌嗪(H7)、N-[2-(甲氨基)乙基]-5-异喹啉磺酰胺(H8)、N-[2-(对溴肉桂氨基)乙基]-5-异喹啉磺酰胺(H89))在细胞调节研究中经常用于阻断信号通路。为了在原子分辨率下阐明抑制机制,并实现基于结构的信号通路潜在治疗调节剂的药物设计,我们测定了与cAPK催化亚基相应复合物的晶体结构。与H7和H8(2.2埃)以及与H89(2.3埃)形成的复合物确定了异喹啉-磺酰胺衍生物在ATP结合位点的结合模式,同时展示了配体诱导的结构变化的影响。酶与抑制剂之间的特异性相互作用包括异喹啉环氮与Val-123主链酰胺连接,以及抑制剂侧链酰胺与Glu-170主链羰基形成键合。蛋白激酶ATP结合位点的保守性使得能够评估这些抑制剂在激酶之间的一般选择性的决定因素。这些结果应该有助于设计具有特定性质的蛋白激酶抑制剂。